Capricor Therapeutics (CAPR) Equity Average (2016 - 2025)
Historic Equity Average for Capricor Therapeutics (CAPR) over the last 15 years, with Q3 2025 value amounting to $94.4 million.
- Capricor Therapeutics' Equity Average rose 13674.41% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 13674.41%. This contributed to the annual value of $84.0 million for FY2024, which is 38873.43% up from last year.
- Per Capricor Therapeutics' latest filing, its Equity Average stood at $94.4 million for Q3 2025, which was up 13674.41% from $116.3 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Equity Average ranged from a high of $136.6 million in Q1 2025 and a low of $471753.5 during Q3 2023
- Moreover, its 5-year median value for Equity Average was $28.0 million (2022), whereas its average is $40.6 million.
- Per our database at Business Quant, Capricor Therapeutics' Equity Average crashed by 9723.76% in 2023 and then surged by 835433.74% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' Equity Average stood at $34.1 million in 2021, then crashed by 60.04% to $13.6 million in 2022, then decreased by 23.51% to $10.4 million in 2023, then skyrocketed by 926.85% to $106.9 million in 2024, then decreased by 11.64% to $94.4 million in 2025.
- Its Equity Average was $94.4 million in Q3 2025, compared to $116.3 million in Q2 2025 and $136.6 million in Q1 2025.